X-ray crystallography study and optimization of novel benzothiophene analogs as potent selective estrogen receptor covalent antagonists (SERCAs) with improved potency and safety profiles-Reference-Cited by-同舟云学术

X-ray crystallography study and optimization of novel benzothiophene analogs as potent selective estrogen receptor covalent antagonists (SERCAs) with improved potency and safety profiles

Published:2023-12 Issue: Volume:141 Page:106919
ISSN:0045-2068
Container-title:Bioorganic Chemistry
language:en
Short-container-title:Bioorganic Chemistry

Author:

Bai Chengfeng,Lv Yang,Xiong Shuangshuang,Wu Shuangjie,Qi Lin,Ren Shengnan,Zhu Meiqi,Dong Haijuan,Shen Hongtao,Li Zhaoxing,Zhu Yinxue,Ye Hui,Hao Haiping,Xiao Yibei,Xiang Hua,Luo Guoshun

Funder

Natural Science Foundation of Jiangsu Province

Double First Class University Plan

Salt Science Research Foundation

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Molecular Biology,Biochemistry

Reference51 articles.

1. Prognostic effect of estrogen receptor status across age in primary breast cancer;Bentzon;Int. J. Cancer,2008

2. Estrogen receptors: therapies targeted to receptor subtypes;Nilsson;Clin. Pharmacol. Ther.,2011

3. Estrogen Receptors as Therapeutic Targets in Breast Cancer;Ariazi;Curr. Top. Med. Chem.,2006

4. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial;Cuzick;Lancet Oncol.,2015

5. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate;Dombernowsky;J. Clin. Oncol.,1998

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multi-component forms of the 2nd generation H1 receptor antagonist drug, Bilastine and its enhanced physicochemical characteristics;Bioorganic Chemistry;2024-10

2. Dual-target inhibitors based on ERα: Novel therapeutic approaches for endocrine resistant breast cancer;European Journal of Medicinal Chemistry;2024-04